Who should use the Gail Model?

The Gail Model is designed for women aged 35-85 without a personal history of breast cancer, ductal carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS). It is not appropriate for women with known BRCA mutations — they should use models like BRCAPRO or Tyrer-Cuzick.

What does 1.7% five-year risk mean?

The 1.7% threshold was chosen because it equals the 5-year risk of a 60-year-old average-risk woman, which was the eligibility criterion for the NSABP P-1 tamoxifen chemoprevention trial. Women at or above this threshold are candidates for chemoprevention.

Does the Gail Model account for BRCA mutations?

No. The Gail Model does not incorporate genetic testing results. Women with strong family histories of breast/ovarian cancer (especially early-onset or bilateral) should be referred for genetic counseling and risk assessment with models that incorporate genetic data (BRCAPRO, Tyrer-Cuzick, CanRisk).

How accurate is the Gail Model?

The Gail Model has good calibration (predicts the correct number of cancers in a population) but moderate discrimination (ability to distinguish who will develop cancer). Its C-statistic is approximately 0.58-0.62, meaning individual predictions have uncertainty. It performs best as a population screening tool rather than individual prediction.

What is the average lifetime risk?

The average US woman has approximately a 12.5% (1 in 8) lifetime risk of breast cancer. This includes all ages from birth to death. Risk varies significantly by decade — most breast cancers occur after age 50.

Should I take tamoxifen if my risk is ≥1.7%?

The decision is individualized based on risk-benefit analysis. Tamoxifen reduces invasive breast cancer by ~49% over 5 years but carries risks of venous thromboembolism, endometrial cancer, and hot flashes. For premenopausal women 35-50, the benefit generally outweighs risk. For postmenopausal women, aromatase inhibitors may be preferred.

Breast Cancer Risk Calculator (Gail Model)

Estimate 5-year and lifetime breast cancer risk using Gail Model factors: age, menarche, first birth, family history, biopsies, and atypical hyperplasia. Includes chemoprevention and screening guid...

⚠️ Important: This is a simplified Gail Model-inspired estimate for educational purposes. For clinical use, refer to the official NCI Breast Cancer Risk Assessment Tool (BCRAT). This tool does not assess BRCA mutation risk — women with strong family histories should be referred for genetic counseling.

Current AgeValid range: 35-85

years

Race/Ethnicity

Age at MenarcheEarlier menarche = more estrogen exposure

Age at First Live Birth

First-Degree Relatives with BCMother, sister, or daughter

Prior Breast Biopsies

Atypical HyperplasiaOn any prior biopsy

Estimated 5-Year Invasive Breast Cancer Risk

2.2%

Average woman same age: 2%

5-Year Risk

2.2%

Above average: May qualify for chemoprevention (tamoxifen/raloxifene); discuss risk-benefit

Lifetime Risk (to age 90)

7.7%

Approximate cumulative risk. Average US woman: ~12.5% (1 in 8).

Relative Risk

1.12×

Compared to average same-age, same-race woman with no risk factors.

Chemoprevention Eligible

Yes (≥ 1.7%)

5-year risk ≥ 1.7% qualifies for tamoxifen, raloxifene, or aromatase inhibitor discussion per NCCN/USPSTF.

MRI Screening Eligible

No (< 20% lifetime)

ACS recommends annual breast MRI + mammography if lifetime risk ≥ 20%.

Average 5-Year Risk (same age)

Population baseline for comparison.

Risk Category Interpretation

5-Year Risk	Category	Typical Review Context
< 1.7%	Average risk	Routine mammographic screening per guidelines
1.7-3%	Above average	May qualify for chemoprevention (tamoxifen/raloxifene); discuss risk-benefit
3-5%	Moderate risk	Strong consideration for chemoprevention; annual mammogram + clinical exam
≥ 5%	High risk	Chemoprevention recommended; consider enhanced screening (MRI)

Chemoprevention Options

Drug	Eligibility	Risk Reduction	Side Effects	Duration
Tamoxifen	Pre- or postmenopausal, ≥35 yr	~49% over 5 years	Hot flashes, VTE, endometrial cancer risk	5 years
Raloxifene	Postmenopausal only	~38% over 5 years	Hot flashes, VTE (lower than tamoxifen)	5 years
Aromatase inhibitors	Postmenopausal, high risk	~53-65% over 5 years	Musculoskeletal pain, osteoporosis risk	5 years

Screening Recommendations by Organization

Organization	Average Risk	High Risk	Genetic
ACS	Annual mammo age 45-54, then biennial	Annual mammo + MRI starting age 30 if ≥20% lifetime risk	BRCA carriers: annual MRI + mammo from age 25-30
USPSTF	Biennial mammo age 40-74	Insufficient evidence for supplemental MRI	Risk assessment for BRCA if family history criteria met
NCCN	Annual mammo starting age 40	Annual mammo + MRI if ≥20% lifetime risk	Time-intensive screening protocol for BRCA carriers
ACR	Annual mammo starting age 40	Annual mammo + MRI if ≥20% lifetime risk	Risk assessment for all women by age 25

Planning notes, formulas, and examples

About the Breast Cancer Risk Calculator (Gail Model)

The Gail Model (also known as the Breast Cancer Risk Assessment Tool, BCRAT) is the most widely used tool for estimating a woman's 5-year and lifetime risk of developing invasive breast cancer. Developed by Dr. Mitchell Gail and colleagues at the National Cancer Institute in 1989, it uses seven key risk factors: age, age at menarche, age at first live birth, number of first-degree relatives with breast cancer, number of prior breast biopsies, presence of atypical hyperplasia, and race/ethnicity.

The model's primary clinical application is identifying women eligible for chemoprevention. The NSABP P-1 trial established the 1.7% 5-year risk threshold for tamoxifen eligibility, while the STAR and MAP.3 trials validated raloxifene and aromatase inhibitors respectively. Women with ≥20% lifetime risk also qualify for enhanced screening with annual breast MRI per ACS guidelines.

It shows an educational Gail-inspired risk estimate, comparison to population averages, chemoprevention eligibility assessment, and comprehensive screening guideline summaries from major organizations. For definitive clinical use, the official NCI BCRAT tool should be used.

When This Page Helps

The Gail Model gives a quick way to frame a woman's baseline breast cancer risk, which helps organize discussions about chemoprevention and screening intensity. This calculator keeps the standard risk inputs together so the 5-year and lifetime estimates can be compared with the thresholds that usually drive preventive planning.

How to Use the Inputs

Enter your current age (valid for women 35-85).
Select your race/ethnicity — the model uses different baseline incidence rates by group.
Enter age at menarche, age at first live birth, family history, and biopsy information.
Review 5-year and lifetime risk estimates vs. population average.
Check chemoprevention eligibility (≥1.7% 5-year risk) and MRI screening eligibility (≥20% lifetime).
Use presets to compare different risk profiles.

Formula used

Gail Model estimates use relative risk multipliers for:
- Age at menarche (earlier = higher risk)
- Age at first live birth (later/nulliparous = higher risk)
- First-degree relatives (each approximately doubles risk)
- Prior biopsies (more biopsies = higher risk)
- Atypical hyperplasia (~2× risk multiplier)
- Race/ethnicity (different baseline incidence rates)

5-year risk = baseline incidence × combined relative risk
Lifetime risk approximated from 5-year projection

Example Calculation

Result: 5-year risk: ~3%.

A 50-year-old white woman with one affected first-degree relative, menarche at 12, first birth at 28, and no biopsies has a 5-year risk of approximately 3%. This exceeds the 1.7% threshold for chemoprevention eligibility. Discussion of tamoxifen or aromatase inhibitor risk/benefit is warranted.

Tips & Best Practices

First-degree relatives means mother, sister, or daughter — not aunts, grandmothers, or cousins.
Atypical hyperplasia on biopsy doubles the risk and is one of the strongest modifiable risk factors.
Chemoprevention decisions should weigh breast cancer risk reduction against drug side effects.
If lifetime risk ≥20%, discuss adding annual breast MRI to mammographic screening.
The Gail Model underestimates risk in women with extensive family histories — consider Tyrer-Cuzick (IBIS) model instead.

The Gail Model: History and Validation

The original Gail Model was published in 1989 and has undergone several updates. The most current version (BCRAT) includes race-specific hazard rates for White, African American, Hispanic, and Asian/Pacific Islander women. It has been validated in over 1 million women through the Breast Cancer Prevention Trial and Nurses' Health Study, confirming accurate population-level calibration.

Beyond the Gail Model: Other Risk Assessment Tools

Several models provide complementary risk assessment. The Tyrer-Cuzick (IBIS) model incorporates second-degree family history, BRCA status, mammographic density, and hormonal factors — providing better discrimination for high-risk women. BRCAPRO estimates BRCA mutation carrier probability. CanRisk (formerly BOADICEA) is the most comprehensive, integrating genetics, polygenic risk scores, and clinical factors into a single model.

Breast Density and Risk

Mammographic breast density is a strong, independent risk factor not captured by the original Gail Model. Women with extremely dense breasts (BI-RADS D) have 4-6 times higher risk than those with fatty breasts. Many states now mandate breast density notification, and supplemental screening (MRI, ultrasound, or contrast-enhanced mammography) is increasingly recommended for dense-breasted women at elevated risk.

Sources & Methodology

Last updated: March 28, 2026

Methodology

This page uses a Gail-inspired educational model to combine the classic Breast Cancer Risk Assessment Tool inputs into rough 5-year and lifetime risk estimates, then compares those estimates with the common planning thresholds shown on the page. It is designed to explain how the standard Gail/BCRAT factors move risk up or down, not to replace the official calculator or a specialist high-risk-breast clinic review.

Because the implementation is intentionally simplified, the output should be treated as educational context. Women with strong family histories, known pathogenic variants, prior thoracic radiation, or dense-breast/high-risk questions that fall outside the Gail framework need more specific tools and clinical counseling.

Sources

Breast Cancer Risk Assessment Tool (National Cancer Institute) — Official Gail/BCRAT implementation that this page references conceptually.
American Cancer Society screening recommendations for women at high risk (American Cancer Society) — High-risk MRI screening threshold context referenced on the page.

Frequently Asked Questions

The Gail Model is designed for women aged 35-85 without a personal history of breast cancer, ductal carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS). It is not appropriate for women with known BRCA mutations — they should use models like BRCAPRO or Tyrer-Cuzick.